Reversion pulmonary fibrosis nano preparation and preparation method thereof

A pulmonary fibrosis and nano-preparation technology, which is applied in the direction of pharmaceutical formulations, medical preparations of non-active ingredients, non-effective ingredients of polymer compounds, etc., can solve the problems of low delivery efficiency and poor targeting, and achieve high-efficiency lung delivery, Achieve specific targeting and prolong circulation time

Active Publication Date: 2019-03-08
CHINA PHARM UNIV
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Nano-preparation has received more and more attention in disease treatment, but nano-preparatio...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Reversion pulmonary fibrosis nano preparation and preparation method thereof
  • Reversion pulmonary fibrosis nano preparation and preparation method thereof
  • Reversion pulmonary fibrosis nano preparation and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Embodiment 1 Synthesis and preparation of nano-preparation components, such as figure 1 Shown:

[0054] 1. Preparation of double-drug / single-drug PLGA-PEG-MAL nanoparticles

[0055] Polymer nanoparticles loaded with anti-pulmonary fibrosis drugs or fluorescent dyes (as a model instead of drugs for formulation tracking) can be prepared by thin film dispersion method, direct titration method and reverse solvent method. In the present invention, the direct titration method is preferably used to prepare PLGA-PEG-MAL nanoparticles loaded with anti-fibrosis drug double / single drug (trametinib and / or astaxanthin). The specific preparation method is as follows:

[0056] Weigh 100 mg PLGA-PEG-MAL and 10 mg double-drug / single-drug and dissolve in 2 mL DMSO solution respectively, and dissolve by ultrasonication. Under stirring conditions, the DMSO solution was added dropwise to 100 mL of pure water, and after stirring was continued for 2 h at room temperature, the unencapsulate...

Embodiment 2

[0080] Example 2 Uptake analysis of nano-preparation at the level of A549 cells and quantitative analysis by flow cytometry

[0081] Nano-preparations of PP / coumarin 6, PPE / coumarin 6, PPR / coumarin 6 and PPER / coumarin 6 were prepared as described in Example 1. A549 cells were divided into 5×10 5 / mL inoculated in 24-well plate, at 37 ℃, 5% CO 2 After 24 hours of adherent growth in the cell culture incubator, the culture medium was sucked off, TGF-β (5 ng / mL) diluted in serum-free medium was added to stimulate 24 hours, and free coumarin 6, PP / coumarin 6 and PP / coumarin diluted in serum-free medium were added respectively. Coumarin 6, PPR / coumarin 6, PPC / coumarin 6 and PPCR / coumarin 6, the concentration of coumarin 6 in each well is 1 μg / mL, 500 μL, and three auxiliary wells are set for each group. Continue culturing for 4 h, wash three times with PBS,

[0082] (1) The uptake of nanoparticles and free coumarin 6 by cells was photographed by laser confocal LSM-700;

[0083...

Embodiment 4

[0085] Example 4 Analysis of lung-specific delivery of nano-preparations coated with fluorescent dyes (DiR) in mice with pulmonary fibrosis

[0086] PP / DiR, PPE / DiR, PPR / DiR and PPER / DiR nano-formulations were prepared as described in Example 1.

[0087] First, 6-8 week-old male C57BL / 6 mice were used for the modeling experiment of the pulmonary fibrosis model, and the lungs of the mice were directly modeled by tracheal intubation. Bleomycin hydrochloride was used as a mouse lung fibrosis inducer during modeling, and the concentration was 2 USP / Kg. After three weeks, the mouse lung fibrosis was formed, and then the nanoparticle tracer experiment was continued. For judging the modeling time of the mouse pulmonary fibrosis model, a large number of literatures have reported that the pulmonary fibrosis of the mouse is in the rapid development stage after three weeks, and the proliferation of circulating fibroblasts in the body is the most obvious. The three-week-old mice were ran...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention discloses a reversion pulmonary fibrosis nano preparation and a preparation method thereof, and relates to a synthetic E5 and polypeptide Z modified nano preparation and a carrier thereof. The nano preparation is capable of, through E5 targeted circulation fibrocyte CXCR4, CCR2 and CCR7 acceptors, reaching a pulmonary fibrosis injured part in a fixed point, and avoiding from being packaged and cleared by in-vivo macrophages and proteins; and through polypeptide Z, specific-targeting alveolar epithelial cells II of a high-expression integrin acceptor AlphavBeta6, and efficiently targeting and delivering the nano preparation. The nano preparation contains an anti-oxidant and/or a fibroblast activation inhibitor. A purpose of reversing pulmonary fibrosis is achieved by controlling an alveolar epithelial cell II oxidative stress level and inhibiting fibroblast activation double-channel control.

Description

technical field [0001] The present invention relates to a circulating fibrocyte-loaded double-drug and / or single-drug nano-preparation for reversing pulmonary fibrosis, in particular to a pulmonary fibrosis-loaded double-drug and / or single-drug nano-preparation targeting circulating fibrocytes in vivo preparation and its application. Background technique [0002] Pulmonary fibrosis is a progressive interstitial lung disease with a high mortality rate, and the survival period is 3-5 years. In recent years, airborne particles (PM 2.5) have been excessively high due to environmental pollution, resulting in damage to alveolar epithelial cells I (AT1) and II (AT2). Among them, AT1 cells have a simple intracellular structure and are mainly responsible for the inhalation of alveolar oxygen and the exhalation of carbon dioxide; AT2 cells are called stem cell-like cells of lung tissue and have the ability of self-renewal. When AT2 is damaged, the proliferative ability of the alveol...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/51A61K47/34A61K47/10A61K47/42A61K31/519A61K31/122A61P11/00
CPCA61K9/5146A61K9/5153A61K9/5169A61K31/122A61K31/519A61P11/00A61K2300/00
Inventor 姜虎林常鑫邢磊
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap